News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Seres Health Makes Push For First Drug, And IPO, Of Microbiome Era



7/17/2014 7:19:54 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The first regulated therapy to emerge from the recent explosion of microbiome research is one step closer. And the company developing it, Seres Health, is stepping toward the first microbiome startup IPO, Xconomy has learned.

The Cambridge, MA startup announced today that its lead product, made from a mix of bacterial spores, has effectively cured 29 of 30 patients who suffered from recurring infection of the potentially deadly bacterium Clostridium difficile, or C. diff.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy


comments powered by Disqus
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES